Valeant CEO Joseph Papa is healthcare's top-paid executive at $62.7 million. But to get that total amount, Papa must improve the long-term financial health of his company—a benchmark that's increasingly tied to executive compensation.
Federal prosecutors on Thursday charged a former Valeant Pharmaceuticals executive and the ex-CEO of a specialty pharmacy for masterminding a multimillion fraud and kickback scheme that promoted the pharmacy's business for their own personal gain.
Pharmacy benefit managers are facing heat for not doing enough to slow down drug price hikes. Modern Healthcare Midwest Bureau Chief Bob Herman recently asked OptumRx CEO Mark Thierer about the controversy swirling around the industry.
Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has soared over the past decade. But the drugmaker didn't budge on its price hikes Thursday.
Valeant Pharmaceuticals replaced Robert Rosiello as chief financial officer as the embattled company attempts to normalize operations amid a host of ongoing investigations and class action lawsuits.
In a recent report to Congress, the CMS said the cost of Medicaid expansion through the Affordable Care Act was $6,366 per person covered for 2015, about 49% higher than previously estimated.
A nimble inside-the-Beltway operative, Stephen Ubl took the reins of the Pharmaceutical Research and Manufacturers of America just as outrage over high drug prices was hitting its peak. In an interview with Modern Healthcare Editor Merrill Goozner, Ubl shares his views on the drug-price debate.
Valeant Pharmaceuticals resolved its default on some of its $30 billion in debt by finally filing its long-overdue U.S. financial report for 2015 on Friday. The badly tarnished Canadian drugmaker also announced a slate of mostly new nominees for elections to its board in June.
The outgoing CEO of embattled drugmaker Valeant Pharmaceuticals will tell lawmakers Wednesday that he was "too aggressive" and made mistakes in significantly hiking prices for several critical medicines, according to testimony provided to the Associated Press.
Lawmakers accused drugmaker Valeant Pharmaceuticals of gouging patients to reward Wall Street investors at a hearing Wednesday focused on the embattled drugmaker's pricing tactics.
Middle-aged white people now account for one-third of all suicides in the U.S., according to the Centers for Disease Control and Prevention. Suicide is the nation’s 10th leading cause of death, and the overall rate rose 24% in 15 years.
Right-to-die advocates in Washington state have created a cheaper alternative mixture of medications to help terminally ill patients legally end their lives after a drug company abruptly hiked the price of a drug commonly used for the purpose.